A contamination control strategy (CCS) is a planned set of controls for microorganisms, endotoxins, pyrogens and particles, derived from an understanding of the product and process. The revised EU GMP Annex 1, published in 2022 and effective from August 2023, requires sterile manufacturers to implement a CCS across the facility that defines all critical control points and assesses how effective every control and monitoring measure is.
Annex 1 lists the elements a CCS should consider, including plant and process design, premises and equipment, personnel, utilities, raw material controls, containers and closures, vendor approval, process risk assessment, process and sterilisation validation, preventive maintenance, cleaning and disinfection, monitoring systems, and prevention mechanisms such as trend analysis, investigation, CAPA and continuous improvement.
Why it matters in GMP
Before the revision, contamination controls were often spread across dozens of SOPs and validation reports with no single view of how they fitted together. Inspectors now ask to see the CCS itself and how it links hazards to controls, monitoring and the evidence that those controls work. A CCS that is written once and never reviewed is a common gap.
- Map each contamination hazard to its controls and the monitoring that proves they work.
- Use quality risk management to justify the strategy.
- Review the CCS periodically and whenever monitoring data or processes change.
How Swat iQua Suite handles it
Swat iQua Suite holds the CCS as a controlled, versioned document per site, optionally scoped to a product version, with an element register that links each hazard to its control, monitoring and effectiveness. The register is editable in draft, approval is e-signed by someone other than the author, and approving a new version supersedes the previous CCS for the same scope.